Figure 5.

Effects of pharmacological inhibitor of IDO1 on body weight, spasms frequency, and metabotype. (a) Body weight gain in pups treated with or without 1-methyltryptphan. n = 14, 10, 20, 15 for NDL, NDL+1-MT, KDL, KDL+1-MT groups, respectively. (b) Spasm frequency in pups treated with or without 1-methyltryptphan. n = 8, 9, 17, 10 for NDL, NDL+1-MT, KDL, KDL+1-MT groups, respectively. (c) Partial least squares discriminant analysis of serum metabolomics pofiles. (d) Discriminant metabolites in serum. (e) Pathway analysis of serum discriminant metabolites. (f) Representative metabolites involved in kynurenine metabolism from serum profiles. n = 10–13 (c–f). (g) Partial least squares discriminant analysis of hippocampal metabolomics pofiles. (h) Discriminant metabolites in hippocampus. (i) Pathway analysis of hippocampal discriminant metabolites. (j) Representative metabolites involved in kynurenine metabolism from hippocampal profiles. n = 10–14 (G–J). (k) Summary of trypophan metabolism affected by 1-MT treatment. Data are presentd as mean±SEM. One-way ANOVA with repeated-measures and Bonferroni post hoc test (a): different letters indicate significant difference, p < 0.05. One-way ANOVA followed by Turkey's post-hoc test (b, f, j): *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. IDO1, indoleamine 2, 3-dioxygenase 1; KAT, kynurenine aminotransferase; NDL, normal diet and intracerebral lesion; KDL, ketogenic diet and intracerebral lesion.